What Does a BRAF V600E Mutation Mean?

This page is for people whose tumor test report shows a BRAF V600E mutation. It explains what the result means, which cancers carry it, and how it can shape treatment.

BRAF is a gene. It makes a protein your cells use to control growth and division. That protein is part of a chain of signals called the MAPK pathway. This pathway normally turns cell growth on and off as needed.

V600E is the name of a specific change in the BRAF gene, called a mutation. The change increases growth-promoting signals through the MAPK pathway. The cell keeps getting a "grow" message even when it should not. That can drive cancer growth.

A BRAF V600E result on a pathology or genomic report means one thing. This specific mutation was found in your test sample. It can affect which drugs are options for you.

BRAF V600E shows up at very different rates depending on the cancer type.

• Melanoma. Found in nearly half of cases.
• Papillary thyroid cancer. Studies report a wide range, roughly 3 in 10 to 9 in 10 cases, depending on the population studied. Many report about 4 to 6 in 10.
• Hairy cell leukemia. NCI calls it a defining genetic feature of the classic form of this leukemia.
• Colorectal cancer. Found in about 10 percent of metastatic cases.
• Non-small cell lung cancer. Found in about 1 to 2 percent of cases.

The same mutation appears across many cancer types. Because of this, the FDA has approved dabrafenib plus trametinib for adults and children 6 and older with advanced solid tumors that have BRAF V600E, whatever the organ. This is called a tumor-agnostic approval. NCI notes it is not indicated for colorectal cancer, because of known resistance to BRAF inhibitors alone.

Finding BRAF V600E often opens the door to targeted therapy. These drugs are built to block the overactive signal the mutation creates. Older chemotherapy instead attacks all fast-growing cells.

• BRAF inhibitors block the mutated BRAF protein directly. Examples are dabrafenib and encorafenib.
• MEK inhibitors block the next step in the same pathway. They are usually given together with a BRAF inhibitor. Examples are trametinib and binimetinib.
• Dabrafenib plus trametinib is the FDA-approved pair for BRAF V600E solid tumors. In metastatic colorectal cancer, NCI reported on a combination of encorafenib, binimetinib, and cetuximab (an EGFR-blocking drug). Ask your team which combination applies to you.

NCI notes that dabrafenib plus trametinib was approved for advanced melanoma, non-small cell lung cancer, and anaplastic thyroid cancer before it was cleared for solid tumors of any type. How well it works varies by cancer type and from person to person.

A positive BRAF V600E result has limits. It does not tell you your stage. It does not predict how your specific tumor will respond. It does not mean every BRAF-targeted drug is approved for your exact cancer type. Drug approvals vary by cancer type and by country. It also does not replace the other things your team weighs, like tumor stage and your overall health. All of these factor into your treatment plan together.

A negative result does not rule out cancer growth through other pathways. Many cancers without BRAF V600E still grow through other mutations.

• Is a BRAF-targeted drug pair an option for my specific cancer type and stage?
• What side effects come with BRAF and MEK inhibitors, and how are they managed?
• Were other biomarkers tested at the same time, such as MSI, HER2, or KRAS?
• If I do not have this mutation, what other treatment options are being considered?

A BRAF V600E result matters for treatment planning. But it is not an emergency finding on its own. It can open up specific drug options. Because of that, ask your care team promptly whether it changes your next treatment step.

• National Cancer Institute — Tumor-Agnostic Cancer Therapies (PDQ)
• National Cancer Institute — FDA Approves Dabrafenib-Trametinib for BRAF-Positive Solid Tumors (melanoma prevalence)
• National Cancer Institute — Targeted Drug Trio for Colorectal Cancer with BRAF Mutations (metastatic colorectal prevalence)
• National Cancer Institute — Combination Therapy Approved for Lung Cancers with BRAF Mutations
• National Cancer Institute — Hairy Cell Leukemia Treatment (PDQ)
• NIH PubMed Central — BRAF mutation in hairy cell leukemia
• NIH PubMed Central — BRAF V600E in thyroid cancer: prognostic uncertainty and therapeutic opportunity